Giuseppe Saglio.

Giuseppe Saglio, M.D reviews ., Dong-Wook Kim, M.D., Ph.D., Surapol Issaragrisil, M.D., Philipp le Coutre, M.D., Gabriel Etienne, M.D., Clarisse Lobo, M.D., Ricardo Pasquini, M.D., Richard E. Clark, M.D., Andreas Hochhaus, M.D., Timothy P. Hughes, M.D., M.B., B.S., Neil Gallagher, M.D., Ph.D., Albert Hoenekopp, M.D., Mei Dong, M.D., Ariful Haque, M.S., Richard A. Larson, M.D., and Hagop M. Kantarjian, M.D. In the International Randomized Study of Interferon and STI571 , imatinib was associated with a superior response rate and improved progression-free survival, in comparison with the previous standard therapy, interferon alfa in addition low-dose cytarabine.1-3 Eight-year follow-up of IRIS revealed that responses to imatinib were had and durable a satisfactory adverse-event profile, with an estimated rate of general survival of 85 percent.4 Despite the positive effect of imatinib, nearly 20 percent of patients who take the medication don't have a complete cytogenetic response, among others may have intolerable side effects or drug resistance over time.

Assessments for virologic end factors were made at a central laboratory at weeks 24 and 48 , with your final clinic go to at week 72 . At each clinic visit, all patients underwent a complete physical safety and evaluation assessment, and blood was used for biochemical and virologic analysis. Safety and Efficacy Safety was assessed by the scholarly study investigators based on adverse occasions reported spontaneously by research participants. In addition, plasma samples had been routinely assessed for hematologic variables . Outcome procedures are described at length in the Supplementary Appendix. Statistical Analysis Detailed information on the procedures used for the statistical analysis comes in the Supplementary Appendix. In brief, an intention-to-treat efficacy evaluation was performed for all sufferers receiving at least one dose of the analysis medication .